What does ipamorelin mass spectrometry confirm in a research lot?
Ipamorelin mass spectrometry confirms whether a measured ion series is consistent with the elemental formula and sequence-related fragments of the named pentapeptide. It does not, by itself, certify chromatographic purity, counter-ion content, moisture or the absence of co-eluting material that lacks a response under the chosen ionisation conditions. The primary identity statement is compositional. The neutral molecule corresponding to Aib-His-D-2-Nal-D-Phe-Lys-NH2 has the formula C38H49N9O5 and a calculated monoisotopic mass of 711.386 Da. Observation of [M+H]+ near m/z 712.393, or [M+2H]2+ near m/z 356.700, supports that composition when the mass error sits inside the window defined for the instrument. Mass error in parts per million is one million times the measured-minus-theoretical difference, divided by the theoretical m/z. A measured [M+H]+ at 712.397 against 712.393 is about 5.6 ppm, which may pass a 10 ppm window and fail a 5 ppm window. The record should quote the window that was actually applied. A matching intact mass still leaves residue order and stereochemistry incompletely proved. Low-energy collision-induced dissociation can support order by generating b and y ions, but D- and L-residues have the same residue mass, so a product-ion spectrum does not assign the configuration of 2-naphthylalanine or phenylalanine. Alpha-aminoisobutyric acid is achiral, yet its presence is a mass feature, not a stereochemical one. A defensible research record therefore treats mass spectrometry as one orthogonal line beside reversed-phase retention and the synthetic description of the reference material. Published urine methods for this peptide class illustrate the same separation of questions: liquid chromatography-mass spectrometry was used to determine intact growth hormone-releasing peptides and major metabolites as distinct analytical targets, rather than as one undifferentiated signal (PMID:21298258). If only an adduct is observed, the identity call should name that adduct rather than imply that the protonated molecule was measured. Area percent, where reported, belongs to the chromatographic purity section and should not be inferred from ion abundance, because electrospray response is compound-dependent and is not a universal mass-fraction detector.
How is the theoretical monoisotopic mass of ipamorelin calculated?
The theoretical mass used in ipamorelin mass spectrometry is obtained from residue masses plus the terminal groups, not from an average molecular weight. Using monoisotopic residue masses rounded to four decimal places, alpha-aminoisobutyric acid contributes 85.0528 Da, histidine 137.0589 Da, 2-naphthylalanine 197.0841 Da, phenylalanine 147.0684 Da and lysine 128.0950 Da. Those five figures sum to 694.3592 Da. Because the C-terminus is a primary amide rather than a carboxylic acid, the intact neutral molecule is that residue sum plus NH3 (17.0265 Da), giving 711.3857 Da, which rounds to 711.386 Da at three decimal places. The same atom count yields the elemental formula C38H49N9O5. Protonated reference values follow directly: [M+H]+ at m/z 712.393 and [M+2H]2+ at m/z 356.700, using a proton mass of 1.0073 Da and dividing the doubly protonated mass by two. A laboratory should record the proton mass and rounding convention it applied, because a 0.001 Da difference can matter inside a 5 ppm window. At m/z 712.393, 5 ppm is about 0.0036 Da and 10 ppm is about 0.0071 Da. On a unit-resolution quadrupole the same ion is observed at nominal m/z 712, and the acceptance test is then the nominal mass plus the fragment pattern, not a parts-per-million error. The isotope envelope is a further check on carbon count. With 38 carbon atoms, the M+1 ion is expected at about 41 percent of the monoisotopic height from 13C alone, before smaller contributions from 15N and 18O. An envelope that is far richer or poorer in M+1 is a reason to question the formula even when the monoisotopic peak sits near the calculated value. Average mass, near 711.9 Da, is not the correct comparator for an electrospray centroid and should not be entered as the theoretical mass on a high-resolution record.
Which charge states and adducts should be expected in an ipamorelin electrospray spectrum?
Electrospray ionisation of this basic pentapeptide commonly yields both singly and doubly charged protonated molecules. Histidine, the N-terminal amine and the lysine side chain provide sites that can carry charge, so [M+2H]2+ is often abundant even though the neutral mass is only 711.386 Da. Identity software should therefore search both m/z 712.393 and m/z 356.700 before a spectrum is called negative. Adducts are a frequent source of mis-assignment. Replacement of a proton by sodium moves the singly charged ion by +21.982 Da, placing [M+Na]+ near m/z 734.375. The potassium adduct [M+K]+ sits near m/z 750.349. These adducts are compositionally the same peptide; they are not related substances. A doubly charged sodium species, [M+H+Na]2+, falls near m/z 367.691 and can be mistaken for a different peptide if the charge state is read incorrectly from the isotope spacing. Spacing of 1.0 Da indicates charge 1+, and spacing of 0.5 Da indicates charge 2+. High-resolution spectra make that distinction routine; nominal-mass spectra require the analyst to infer charge from the selected precursor and from known fragment offsets. In-source fragmentation can generate ions that coincide with truncated sequences. Those ions should be labelled as source artefacts when they rise and fall with the intact precursor and lack a distinct chromatographic apex. Published high-resolution screening of prohibited small peptides by nano-liquid chromatography and a benchtop quadrupole Orbitrap shows why accurate mass and tandem spectra are used together for this molecular-weight range: a precursor mass narrows the elemental candidates, and product ions test whether the candidate sequence is plausible (PMID:22901302). A research spectrum file should store polarity, the observed m/z, the assigned charge, any adduct annotation and the resolving power or quadrupole isolation width. Without those fields, a later reader cannot tell a sodium adduct from a genuine +22 Da modification.
How do tandem fragment ions support an ipamorelin sequence assignment?
Intact mass fixes composition more tightly than it fixes order. Tandem mass spectrometry addresses order by breaking amide bonds and reading the resulting b and y series. For an amidated pentapeptide the y ions retain the C-terminal amide, so the smallest C-terminal fragment that includes lysinamide is a direct check that the chain has not been written as the free acid. The protonated y1 ion expected for C-terminal lysinamide is the protonated amino-acid amide near m/z 146.13. The corresponding free-acid y1 sits about 0.98 Da higher, so that comparison already separates an amide-terminated reference from an acid-terminated analogue. Complementary b ions, counted from the N-terminus, locate alpha-aminoisobutyric acid as an 85.053 Da increment if that residue is N-terminal, which is the expected arrangement for this sequence. Internal fragments and immonium ions add residue-specific evidence that does not depend on a complete ladder. Histidine commonly yields an immonium ion near m/z 110.07, phenylalanine near m/z 120.08, and 2-naphthylalanine an immonium-type ion near m/z 170.10, reflecting the larger aromatic side chain. Observation of the naphthyl-related ion is particularly useful because few proteinogenic residues produce a fragment at that mass. Absence of one immonium ion is not proof of absence of the residue, because immonium yield depends on collision energy. A stronger assignment is a run of consecutive ions that cover each peptide bond, acquired at a stated collision energy and compared with a qualified reference spectrum under the same conditions. Sequence isomers that merely swap two residues share the precursor mass but shift the internal fragment masses; that is the practical reason a single precursor ion is insufficient. Targeted urine methods have used selected product ions to determine growth hormone-releasing peptides and metabolites when a full scan is not the screening format (PMID:21298258). High-resolution product-ion spectra, as in quadrupole-Orbitrap methods for small prohibited peptides, additionally test the elemental composition of each fragment rather than only its nominal mass (PMID:22901302). Neither format assigns D versus L configuration. Configuration remains a chromatographic and synthetic-record question, not a low-energy fragmentation question.
How do mass shifts and published LC-MS screens separate intact ipamorelin from related signals?
Related-substance reading starts from defined mass shifts, not from peak area. Conversion of the C-terminal amide to the carboxylic acid adds 0.9840 Da, so the protonated free acid lies near m/z 713.377. The 13C isotope of intact [M+H]+ lies near m/z 713.396. The gap is only 0.019 Da. At m/z 713, separating that gap needs resolving power on the order of 40,000. A unit-resolution quadrupole cannot make the distinction, and a distorted isotope cluster on a low-resolution trap is not sufficient evidence either way. An identity specification for the amidated peptide should therefore list both theoretical masses and require charge-state-aware isotope inspection. Truncation shifts equal the lost residue mass: 85.053 Da for alpha-aminoisobutyric acid, 137.059 Da for histidine and 197.084 Da for 2-naphthylalanine. Each truncated candidate must also be tested as amide or acid, because those changes are independent. A peak at a truncation mass may be a synthesis deletion, an in-source fragment or a matrix peptide. Chromatographic apex, a blank trace and whether the ion tracks the intact precursor separate those explanations without turning the certificate into a method procedure. Isobaric peptides can share nominal m/z 712 and still differ in formula. Accurate mass or product ions are required to split them. Published work supplies the interpretive frame for these distinctions. Liquid chromatography-mass spectrometry of growth hormone-releasing peptides and major metabolites in urine reported intact chains and metabolites as separate targets (PMID:21298258). Nano-liquid chromatography with a benchtop quadrupole Orbitrap showed the value of accurate-mass tandem spectra for small prohibited peptides in urine (PMID:22901302). A horse-plasma method for seven bioactive peptides underlines the matrix contrast: protein-rich plasma does not share the ion-suppression profile of urine, so a urine mass window is not automatic evidence for a plasma result (PMID:23318763). Metabolism studies used mass spectrometry to assign modified products of this peptide class as discrete species rather than as anonymous impurity area (PMID:23101768). The lot record should name the matrix the method was built for, the analyser type, nominal versus accurate mass, the ions used for the identity call, and the reference used for retention and fragments. A related-mass row, listing observed m/z, charge, proposed shift, mass error and fragment support, must stay outside the intact-peptide identity statement.
Frequently asked questions
Does an ipamorelin mass spectrum report chromatographic purity?
No. An electrospray spectrum reports ions that the chosen ionisation mode and analyser can detect. A quiet spectrum can coexist with a UV-active impurity that ionises poorly, and a minor component can look abundant if its response is high. Chromatographic purity remains an area measurement at a stated wavelength and integration setting. The spectrum answers a different question: whether the principal ion matches the expected composition and fragment map. Both results may appear on one research record, but neither replaces the other.
Can tandem mass spectrometry assign D-residues in ipamorelin?
No. D-2-naphthylalanine and D-phenylalanine have the same residue masses as the corresponding L-forms, and low-energy collision-induced dissociation does not label configuration. Alpha-aminoisobutyric acid is not chiral. A product-ion match can support residue order and elemental composition, not stereochemistry. Where configuration is part of the identity specification, it has to rest on the synthetic description or on a qualified reference compared by retention, not on the m/z list alone.
Why are m/z 712.393 and m/z 356.700 both relevant?
They represent one neutral molecule in two charge states. The first is [M+H]+ and the second is [M+2H]2+, using the calculated monoisotopic mass of 711.386 Da. Basic sites associated with histidine and lysine make the doubly charged ion common in positive electrospray, even for a peptide of this modest mass. Searching only one charge state can produce a false negative. Charge is read from isotope spacing: about 1 Da for the singly charged ion and about 0.5 Da for the doubly charged ion.
What mass shift separates the C-terminal amide from the free acid?
Replacement of the amide by a carboxylic acid adds 0.984 Da. The protonated acid falls near m/z 713.377, close to the 13C peak of intact [M+H]+ near m/z 713.396. That 0.019 Da gap is invisible on a unit-resolution instrument. Separating it at this m/z needs resolving power on the order of 40,000, plus careful picking of the monoisotopic peak. A specification should list both theoretical masses so the acid is not reported as an isotope of the amide.
Is a published transition list enough to identify a research lot?
No. Published liquid chromatography-mass spectrometry methods show how intact peptides and related species were measured in named matrices, but a research record still needs data acquired on the lot being documented. Matrix, analyser type and collision energy change which ions are abundant. Transcribing a published ion list without a lot spectrum does not confirm identity. The record should cite the method and attach the measured m/z, the mass error and the fragment comparison actually obtained.
How should sodium and potassium adducts be recorded?
They are the same peptide with a different charge carrier, not related substances, when the mass defect and fragment offsets agree. [M+Na]+ lies near m/z 734.375 and [M+K]+ near m/z 750.349 on the mass scale used in this article. The annotation should state the adduct, the charge and the neutral mass implied after removing the carrier. A genuine modification near +22 Da will not show the sodium mass defect and will not collapse to the intact neutral mass of 711.386 Da after that correction.
References
- PMID:21298258 — Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry — Anal Bioanal Chem — 2011
- PMID:22901302 — Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry — J Chromatogr A — 2012
- PMID:23101768 — Metabolism of growth hormone releasing peptides — Anal Chem — 2012
- PMID:23318763 — Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry — Anal Bioanal Chem — 2013
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
